Published in Obes Surg on May 24, 2008
Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology (2009) 4.82
Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment Pharmacol Ther (2010) 2.28
An apoptosis panel for nonalcoholic steatohepatitis diagnosis. J Hepatol (2011) 1.98
A positive feedback loop between RIP3 and JNK controls non-alcoholic steatohepatitis. EMBO Mol Med (2014) 1.28
Adipokines in nonalcoholic steatohepatitis: from pathogenesis to implications in diagnosis and therapy. Mediators Inflamm (2009) 1.26
Multiple hits, including oxidative stress, as pathogenesis and treatment target in non-alcoholic steatohepatitis (NASH). Int J Mol Sci (2013) 1.25
Apoptosis in nonalcoholic fatty liver disease: diagnostic and therapeutic implications. Expert Rev Gastroenterol Hepatol (2011) 1.22
Inflammation and fibrogenesis in steatohepatitis. J Gastroenterol (2012) 1.21
A phase 2, randomized, double-blind, placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis. Hepatology (2011) 1.12
Histopathological diagnosis of non-alcoholic and alcoholic fatty liver disease. Virchows Arch (2011) 1.07
Noninvasive biomarkers in non-alcoholic fatty liver disease: current status and a glimpse of the future. World J Gastroenterol (2014) 1.04
Noninvasive biomarkers for the diagnosis of steatohepatitis and advanced fibrosis in NAFLD. Biomark Res (2013) 1.03
Mechanisms and biomarkers of apoptosis in liver disease and fibrosis. Int J Hepatol (2012) 1.02
Short-term exercise reduces markers of hepatocyte apoptosis in nonalcoholic fatty liver disease. J Appl Physiol (1985) (2012) 0.96
Serum markers of hepatocyte death and apoptosis are non invasive biomarkers of severe fibrosis in patients with alcoholic liver disease. PLoS One (2011) 0.95
[Histopathological diagnosis of non-alcoholic and alcoholic fatty liver disease. Grade 2 consensus-based guidelines]. Pathologe (2010) 0.90
Adiponectin: a key playmaker adipocytokine in non-alcoholic fatty liver disease. Clin Exp Med (2013) 0.88
Performance of Serum microRNAs -122, -192 and -21 as Biomarkers in Patients with Non-Alcoholic Steatohepatitis. PLoS One (2015) 0.86
An Endocrine Perspective of Nonalcoholic Fatty Liver Disease (NAFLD). Ther Adv Endocrinol Metab (2011) 0.86
Cytokeratin 18, alanine aminotransferase, platelets and triglycerides predict the presence of nonalcoholic steatohepatitis. PLoS One (2013) 0.85
Adipose tissue and adipokines: the association with and application of adipokines in obesity. Scientifica (Cairo) (2014) 0.84
Cytokeratin-18 fragments and biomarkers of the metabolic syndrome in nonalcoholic steatohepatitis. World J Gastroenterol (2009) 0.84
Non-invasive Testing for NASH and NASH with Advanced Fibrosis: Are We There Yet? Curr Hepatol Rep (2015) 0.84
Crosstalk between angiogenesis, cytokeratin-18, and insulin resistance in the progression of non-alcoholic steatohepatitis. World J Gastroenterol (2009) 0.83
Significance of serum adiponectin levels in patients with chronic liver disease. Clin Sci (Lond) (2010) 0.83
Elevated serum CK18 levels in chronic hepatitis C patients are associated with advanced fibrosis but not steatosis. J Viral Hepat (2011) 0.83
Hepatic reticuloendothelial system cell iron deposition is associated with increased apoptosis in nonalcoholic fatty liver disease. Hepatology (2013) 0.83
Combined Serum Biomarkers in Non-Invasive Diagnosis of Non-Alcoholic Steatohepatitis. PLoS One (2015) 0.82
Non-invasive Diagnosis of Fibrosis in Non-alcoholic Fatty Liver Disease. J Clin Exp Hepatol (2012) 0.82
Non-alcoholic fatty liver diseases: update on the challenge of diagnosis and treatment. Clin Mol Hepatol (2016) 0.82
Keratins: Biomarkers and modulators of apoptotic and necrotic cell death in the liver. Hepatology (2016) 0.80
Noninvasive Assessment of Fibrosis in Patients with Nonalcoholic Fatty Liver Disease. Int J Endocrinol (2015) 0.80
A "biomarker biopsy" for the diagnosis of NASH: promises from CK-18 fragments. Obes Surg (2008) 0.79
Diagnosis of alcoholic liver disease. World J Gastroenterol (2014) 0.79
Association of adiponectin protein and ADIPOQ gene variants with lumbar disc degeneration. Exp Ther Med (2014) 0.78
Resistin expression correlates with steatohepatitis in morbidly obese patients. Surg Endosc (2012) 0.78
Serum cell death biomarkers for prediction of liver fibrosis and poor prognosis in primary biliary cirrhosis. PLoS One (2015) 0.78
Serum immunoglobulin A concentration is a reliable biomarker for liver fibrosis in non-alcoholic fatty liver disease. World J Gastroenterol (2014) 0.78
Biomarkers in nonalcoholic fatty liver disease: a new era in diagnosis and staging of disease in children. J Pediatr Gastroenterol Nutr (2010) 0.78
Metabolic aspects of adult patients with nonalcoholic fatty liver disease. World J Gastroenterol (2016) 0.77
Biomarkers for noninvasive biochemical diagnosis of nonalcoholic steatohepatitis: tools or decorations? World J Gastroenterol (2009) 0.77
Poor Inter-test Reliability Between CK18 Kits as a Biomarker of NASH. Dig Dis Sci (2015) 0.76
Roux-En Y Gastric Bypass Results in Long-Term Remission of Hepatocyte Apoptosis and Hepatic Histological Features of Non-alcoholic Steatohepatitis. Front Physiol (2016) 0.75
Apoptosis and diagnosis of nonalcoholic steatohepatitis. Korean J Hepatol (2011) 0.75
Diagnostic Value of CK-18, FGF-21, and Related Biomarker Panel in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Biomed Res Int (2017) 0.75
Keratin 18, Apoptosis, and Liver Disease in Children. Curr Pediatr Rev (2011) 0.75
Nonalcoholic fatty liver disease: Diagnostic biomarkers. World J Gastrointest Pathophysiol (2017) 0.75
Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology (2002) 9.35
A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med (2006) 7.35
Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med (2007) 6.11
Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med (2003) 5.97
Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med (2006) 5.65
Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med (2003) 4.12
Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology (2006) 3.80
Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol (2011) 3.67
Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology (2010) 3.57
Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality. Hepatology (2011) 3.55
Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med (2005) 3.46
Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology (2004) 3.19
A Phase 3 Trial of Sebelipase Alfa in Lysosomal Acid Lipase Deficiency. N Engl J Med (2015) 2.77
Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology (2003) 2.66
The combination of ribavirin and peginterferon is superior to peginterferon and placebo for children and adolescents with chronic hepatitis C. Gastroenterology (2010) 2.48
Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: a population-based study. Gut (2010) 2.46
Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology (2006) 2.22
Anthropometric and clinical factors associated with mortality in subjects with nonalcoholic fatty liver disease. Dig Dis Sci (2012) 2.11
A biomarker panel for non-alcoholic steatohepatitis (NASH) and NASH-related fibrosis. Obes Surg (2011) 1.79
Apnoeic-hypopnoeic episodes during obstructive sleep apnoea are associated with histological nonalcoholic steatohepatitis. Liver Int (2008) 1.74
Efficacy and safety of boceprevir plus peginterferon-ribavirin in patients with HCV G1 infection and advanced fibrosis/cirrhosis. J Hepatol (2012) 1.71
Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders. J Hepatol (2003) 1.62
Malignant hepatic angiomyolipoma: report of a case and review of literature. Am J Surg Pathol (2008) 1.58
A systems biology approach to the pathogenesis of obesity-related nonalcoholic fatty liver disease using reverse phase protein microarrays for multiplexed cell signaling analysis. Hepatology (2007) 1.54
Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients. Obes Surg (2005) 1.52
Toward more transparent and reproducible omics studies through a common metadata checklist and data publications. OMICS (2014) 1.49
Laser capture microdissection and protein microarray analysis of human non-small cell lung cancer: differential epidermal growth factor receptor (EGPR) phosphorylation events associated with mutated EGFR compared with wild type. Mol Cell Proteomics (2008) 1.44
Validation of endogenous reference genes for qRT-PCR analysis of human visceral adipose samples. BMC Mol Biol (2010) 1.42
Nonalcoholic fatty liver disease in lean individuals in the United States. Medicine (Baltimore) (2012) 1.31
A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease. Hepatology (2005) 1.29
Secreted neutral metalloproteases of Bacillus anthracis as candidate pathogenic factors. J Biol Chem (2006) 1.28
Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol (2009) 1.25
Efficacy and safety of entecavir in patients with chronic hepatitis B and advanced hepatic fibrosis or cirrhosis. Am J Gastroenterol (2008) 1.17
Hepatic gene expression in patients with obesity-related non-alcoholic steatohepatitis. Liver Int (2005) 1.13
Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimens. Hepatology (2014) 1.10
Farglitazar lacks antifibrotic activity in patients with chronic hepatitis C infection. Gastroenterology (2010) 1.07
Obesity-related differential gene expression in the visceral adipose tissue. Obes Surg (2005) 1.06
Expression of cytokine signaling genes in morbidly obese patients with non-alcoholic steatohepatitis and hepatic fibrosis. Obes Surg (2009) 1.04
Gene expression of leptin, resistin, and adiponectin in the white adipose tissue of obese patients with non-alcoholic fatty liver disease and insulin resistance. Obes Surg (2006) 1.03
A network-based approach to prioritize results from genome-wide association studies. PLoS One (2011) 1.03
Contrasting uptake routes and tissue distributions of inorganic and methylmercury in mosquitofish (Gambusia affinis) and redear sunfish (Lepomis microlophus). Environ Toxicol Chem (2006) 1.02
The association of genetic variants with hepatic steatosis in patients with genotype 1 chronic hepatitis C infection. Dig Dis Sci (2012) 1.01
Combination HBV therapy is linked to greater HBV DNA suppression in a cohort of lamivudine-experienced HIV/HBV coinfected individuals. AIDS (2009) 1.01
Depression in patients with nonalcoholic fatty liver disease and chronic viral hepatitis B and C. Psychosomatics (2011) 0.98
Evidence for the ectopic synthesis of melanin in human adipose tissue. FASEB J (2008) 0.98
What is hidden in the pannexin treasure trove: the sneak peek and the guesswork. J Cell Mol Med (2006) 0.98
Early gene expression profiles of patients with chronic hepatitis C treated with pegylated interferon-alfa and ribavirin. Hepatology (2009) 0.96
Effective antiprotease-antibiotic treatment of experimental anthrax. BMC Infect Dis (2005) 0.96
Hepatitis C virus infection, age, and Hispanic ethnicity increase mortality from liver cancer in the United States. Clin Gastroenterol Hepatol (2010) 0.95
Acceleration of epithelial cell syndecan-1 shedding by anthrax hemolytic virulence factors. BMC Microbiol (2006) 0.95
Predictors of all-cause mortality and liver-related mortality in patients with non-alcoholic fatty liver disease (NAFLD). Dig Dis Sci (2013) 0.95
A comparative analysis of relative occurrence of transcription factor binding sites in vertebrate genomes and gene promoter areas. Bioinformatics (2005) 0.93
PPARgamma activation by thiazolidinediones (TZDs) may modulate breast carcinoma outcome: the importance of interplay with TGFbeta signalling. J Cell Mol Med (2007) 0.93
Hepatitis B-associated fibrosis and fibrosis/cirrhosis regression with nucleoside and nucleotide analogs. Expert Rev Gastroenterol Hepatol (2012) 0.92
Protein partners of KCTD proteins provide insights about their functional roles in cell differentiation and vertebrate development. Bioessays (2013) 0.91
Genetic and functional characterization of the N-terminal region of the hepatitis C virus NS2 protein. J Virol (2013) 0.90
Hepatic gene expression of Caucasian and African-American patients with obesity-related non-alcoholic fatty liver disease. Obes Surg (2010) 0.90
Metabolic syndrome after laparoscopic bariatric surgery. Obes Surg (2008) 0.89
Degradation of circulating von Willebrand factor and its regulator ADAMTS13 implicates secreted Bacillus anthracis metalloproteases in anthrax consumptive coagulopathy. J Biol Chem (2008) 0.89
Carnosine [corrected] increases efficiency of DOPA therapy of Parkinson's disease: a pilot study. Rejuvenation Res (2008) 0.88
Molecular signature of adipose tissue in patients with both non-alcoholic fatty liver disease (NAFLD) and polycystic ovarian syndrome (PCOS). J Transl Med (2013) 0.88
Non-random fragmentation patterns in circulating cell-free DNA reflect epigenetic regulation. BMC Genomics (2015) 0.88
Expression of genes for microRNA-processing enzymes is altered in advanced non-alcoholic fatty liver disease. J Gastroenterol Hepatol (2013) 0.88
Conformational analysis of the carboxy-terminal tails of human beta-tubulin isotypes. Biophys J (2007) 0.88
Comparative analysis of essential collective dynamics and NMR-derived flexibility profiles in evolutionarily diverse prion proteins. Prion (2011) 0.87
Gene expression patterns in hepatic tissue and visceral adipose tissue of patients with non-alcoholic fatty liver disease. Obes Surg (2007) 0.87
Association of serum adipocytokines with hepatic steatosis and fibrosis in patients with chronic hepatitis C. Digestion (2010) 0.87
Ledipasvir/sofosbuvir regimens for chronic hepatitis C infection: Insights from a work productivity economic model from the United States. Hepatology (2015) 0.86
Effects of temperature on the p53-DNA binding interactions and their dynamical behavior: comparing the wild type to the R248Q mutant. PLoS One (2011) 0.86
Association of obestatin, ghrelin, and inflammatory cytokines in obese patients with non-alcoholic fatty liver disease. Obes Surg (2011) 0.85